Kenvue Inc. (NYSE:KVUE) Stock Has Consensus Price Target of $19.00

Shares of Kenvue Inc. (NYSE:KVUE) have received an average recommendation of “Hold” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $18.43.

Several equities analysts have recently weighed in on KVUE shares. Barclays increased their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. UBS Group cut their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th.

Hedge Funds Weigh In On Kenvue

Hedge funds have recently made changes to their positions in the business. Johnson Financial Group Inc. bought a new stake in shares of Kenvue in the 2nd quarter valued at approximately $26,000. CoreCap Advisors LLC grew its holdings in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the last quarter. GK Wealth Management LLC bought a new position in Kenvue in the 3rd quarter worth about $27,000. MV Capital Management Inc. bought a new position in Kenvue in the fourth quarter worth approximately $28,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Kenvue during the 2nd quarter worth $35,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $17.80 on Tuesday. Kenvue has a 52-week low of $14.02 and a 52-week high of $20.13. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm’s 50-day moving average price is $18.41 and its 200-day moving average price is $18.18. The company has a market cap of $34.20 billion, a PE ratio of 20.47, a PEG ratio of 1.62 and a beta of 0.48.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 EPS. As a group, analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were given a dividend of $0.21 per share. The ex-dividend date was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.7%. Kenvue’s payout ratio is 96.55%.

About Kenvue

Kenvue Inc (NYSE: KVUE) is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue’s principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson’s consumer health business and became an independent publicly traded company in 2023.